
Prelude Therapeutics (PRLD) Stock Forecast & Price Target
Prelude Therapeutics (PRLD) Analyst Ratings
Bulls say
Prelude Therapeutics is supported by a pipeline focused on high-unmet-need oncology targets, including selective KAT6A degraders, mutant selective JAK2V617F JH2 inhibitors, and next-generation degrader antibody conjugates with transformative potential. Its 3Q26 net loss of $0.12 per share was in line with expectations, with R&D of about $14.8M, SG&A of $5.1M, and cash, cash equivalents, and marketable securities of roughly $142.7M. That balance sheet should fund operations into 2Q28, while upcoming catalysts in ASH 2026, SABCS 2026, 1H27, and 2H27 provide multiple opportunities to validate the platform and expand partnering value.
Bears say
Prelude Therapeutics is a high-risk, pre-commercial oncology name whose valuation depends heavily on clinical execution rather than current earnings power. Its focus on selective KAT6A degraders, mutant selective JAK2V617F JH2 inhibitors, and degrader antibody conjugates offers scientific upside, but the company remains exposed to the binary risk that these programs fail to deliver transformative data or regulatory momentum. With no mention of profitability or recurring revenue support, the stock’s fundamentals appear fragile and highly dependent on pipeline progress in a competitive precision oncology market.
This aggregate rating is based on analysts' research of Prelude Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Prelude Therapeutics (PRLD) Analyst Forecast & Price Prediction
Start investing in Prelude Therapeutics (PRLD)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Prelude Therapeutics (PRLD) Forecast
Prelude Therapeutics (PRLD) Analyst Forecast & Price Prediction
Start investing in Prelude Therapeutics (PRLD)
Order type
Buy in
Order amount
Est. shares
0 shares